

# Critical Illness Pricing: Can Prices get any Lower?

Matthew Smith, Pacific Life Re





Can Prices get any lower?


stise ship leadership and Meetings arties and the future single society and profile on the fitting society and profile on the fitting society and the future signal society and the fitting signal support of the fitting society and the fitting signal society and the fitting signal society and so

### Themes...

- How critical illness pricing compares with term assurance
- Historic changes in attitude to critical illness pricing
- Potential drivers to tumbling CI prices
- Are we missing anything. Definition creep, trend risk and more...
- Lessons from around the Globe




- Premium Rates in the Recent Past



Institute and Faculty of Actuaries

- And as a % of 2004 rates



### - Potential Drivers for Price Reductions



- Reinsurer morbidity basis (base tables, future trends)
- Reinsurer margins (capital, expenses, margins)
- Quota share %



- Morbidity basis (base tables, future trends)
- Lapse basis

Margins & Competition


- Expense reductions, commission rates
- Margin Cuts
- Capital & guarantee loadings


Let's focus on the morbidity basis...



### **Mortality vs Morbidity Pricing**

- History of Critical Illness as a Product





# **Mortality vs Morbidity Pricing**

- How does Pricing Compare to Mortality?

"Mortality rates are more complicated than morbidity rates... for the former, you have to fall ill <u>and</u> die, not just fall ill"




Healthy Death from non-CI cause Critical Dead Illness


Clearly this is nonsense...



### **Mortality vs Morbidity Pricing**

- Perception of Greater Uncertainty around Morbidity Pricing?








- Growing coverage... trends

#### **Average Number of Critical Illness Conditions**





- Growing coverage... trends

#### Phase I

- ABI Conditions
- Aplastic Anaemia
- Bacterial Meningitis
- Creutzfeldt-Jacob Disease
- Dementia
- Liver Failure

#### Phase II

- Cardiomyopathy
- Encephalitis
- Multiple System Atrophy
- Open Heart Surgery
- Primary Pulmonary Hypertension
- Progressive Supranuclear Palsy
- Respiratory Failure
- Systematic Lupus Erythematosis


#### Phase III

- Partial Payments
- Benign Spinal Cord Tumour
- Cardiac Arrest
- Chronic Rheumatoid Arthritis
- Pulmonary artery surgery
- Pneumonectomy
- · Devic's Disease
- Muscular Dystrophy

Etcetera...



- Growing coverage... costing



Examples...

Creutzfeldt-Jacob Disease Progressive Supranuclear Palsy

Bacterial Meningitis
Systematic Lupus Erythematosis


Cardiomyopathy
Chronic Rheumatoid Arthritis

Increasing Incidence/ reducing overlap




- Growing coverage... price impact

Conclusion?







- Treating Customers Fairly & Non-Disclosure...claims paid



- TCF & Non-Disclosure...claims declined for non-disclosure




- Treating Customers Fairly & Non-Disclosure... impact on claims




- Treating Customers Fairly & Non-Disclosure... price impact

Conclusion?





- Definition Drift...claims declined for not meeting the definition



Source: Industry
Claims Paid
Publications & own
calculations



- Definition Drift... claims paid examples where definition not met

Case Study	% Paid Where definition failed
MI – Infero basal hypokinesis	100%
MI - Mildly impaired systolic function	75%
Dilated cardiomyopathy – controlled well	56%
Sub-arachnoid – no sequelae	55%
Acoustic neuroma with surgery	45%
Possible MS (some kind of neurological disorder)	40%
One episode definite MS – full recovery	27%
Inoperable Glioma – no symptoms	25%


Increasing Severity

Source: Pacific Life Re's "Grey Claims" Survey 2010



- Definition Drift ... price impact

Conclusion?





- Data & Pricing Uncertainty...comparison with Mortality

### Mortality

- Established CMI investigation
- History of mortality tables
- High volumes of internal data

### Morbidity


- Early reliance on population data
- Growing CMI investigation
- Tables in their infancy
- Anti-selection unclear
- Growing condition coverage

# Is this changing?



- Data & Pricing Uncertainty...Growing CMI Dataset

#### **Cumulative Claims by Calendar Year in the CMI Investigation**




Source: CMI

■ All Claims ■ Duration 5+ Claims Only



- Data & Pricing Uncertainty...Growing CMI Dataset

#### 1 in 200 Confidence Intervals Around Observed Claims



--- All Claims Confidence Intervals

--- 5+ Confidence Intervals




- Data & Pricing Uncertainty...but not that simple

Mix of products, underwriting years	Relevance to prospective experience is not clear	
CMI methodology not perfect	Continually evolving	
Select shape	Limited ultimate claims, and particularly difficult to quantify given above	
Age shape	Credibility is limited at the table extremes and experience for minor conditions yet to emerge	


- Data & Pricing Uncertainty... price impact

(Possible)Conclusion?






- Trends... what conditions matter for males?




- Trends... what conditions matter for females?



- Trends... cancer...the ups

#### **Breast Cancer Incidence as % of 1971 (Females)**




Source: ONS Cancer Registry



- Trends... cancer...the ups

#### **Colorectal Cancer Incidence as % of 1971 (Males)**




Source: ONS Cancer Registry



- Trends... cancer...the ups

#### Melanoma Incidence as % of 1971 (Both)




Source: ONS Cancer Registry



- Trends... cancer...the ups

#### **Prostate Cancer Incidence as % of 1971 (Males)**




Source: ONS Cancer Registry



- Trends... cancer...the ups

#### **Testicular Cancer Incidence as % of 1971 (Males)**




Source: ONS Cancer Registry



- Trends... cancer...the ups

#### Thyroid Cancer Incidence as % of 1971 (Both)




Source: ONS Cancer Registry



- Trends... cancer...the downs

#### Lung Cancer Incidence as % of 1971 (Both)




Source: ONS Cancer Registry



- Trends... cancer...the downs

#### **Cervical Cancer Incidence as % of 1971 (Females)**




Source: ONS Cancer Registry



- Trends... cancer...the downs

#### Stomach Cancer Incidence as % of 1971 (Both)




Source: ONS Cancer Registry



- Trends... overall cancer

#### Cancer Incidence as % of 1971 (Both)




Source: ONS Cancer Registry



26 May 2015

- Trends... does the mortality component help?

#### Residual Deaths as % of 1971 (Both)



Source: ONS Cancer Registry



- Trends... what about the cardio-vascular conditions


Condition	Trends
Heart Attack	<b>V</b> /
Stroke	<b>V</b> /
Coronary Artery Bypass-grafts	



26 May 2015

- Trends... price impact

Conclusion?






- Any others...?

	Impact?
Distribution management	
BMI/alcohol	
Underwriting Developments	??
Persistency	??




- Thyroid Cancer in Korea








- Melanoma in Australia








- Prostate Cancer in North America/Australia








- Colorectal Cancer in Asia











# **Summary**

- Can prices get any lower?

It's a surprise they've reduced so much!

- · Given the movements in declined claims
- And the increasing coverage/definition drift
- As well as general cancer trends

Still a risky product

- Uncertainties relative to mortality pricing are still present
- Despite the growing volumes of data
- Should note what has happened around the world

**Evolving** 

- Coverage is growing
- Need to be ready for any surprises
- Care required over definition creep and declined claims trends



# **Summary**

#### - Possible Conclusions

### Pricing Discipline

- Ensure margins vs mortality are sensible
- Emerging experience is uncertain given complexity of select discounts and changing distribution landscape

#### Definition Maintenance

- Consider size related Thyroid cancer exclusions
- General exclusion of nano-sized cancers
- Tiered definitions

# Understanding the Risks

- Internal Model Calibration
- More research (working parties etc)



# Questions

# Comments

Expressions of individual views by members of the Institute and Faculty of Actuaries and its staff are encouraged.

The views expressed in this presentation are those of the presenter.

